Desoximetasone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Desoximetasone: From Inflammatory Skin Conditions to Alopecia Areata
One-Sentence Summary
Desoximetasone is a potent topical corticosteroid originally used for inflammatory skin conditions such as eczema, dermatitis and discoid lupus erythematosus. The TxGNN model predicts it may be effective for alopecia areata, with no registered clinical trials and 1 publication (a randomized, double-blind, placebo-controlled trial) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Inflammatory skin conditions, including atopic eczema, contact dermatitis, seborrheic dermatitis and discoid lupus erythematosus (the Canadian licence records contain no indication text) |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 0.9992 |
| Evidence Level | L2 |
| Canada Market Status | Marketed (marketed DINs: 4 of 4) |
| Number of DINs | 4 (marketed: 4) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, desoximetasone is a topical corticosteroid. Its pharmacology record lists the glucocorticoid receptor (NR3C1) as its target. Drugs of this class have anti-inflammatory and immunosuppressive activity.
Alopecia areata is a T-cell-mediated autoimmune disease in which immune cells attack the hair follicle. Topical corticosteroids are an established treatment class for it, because they suppress the inflammation around the follicle. The drug’s original indications (eczema, dermatitis, lupus erythematosus and others) are also inflammatory or immune-driven skin diseases. This makes the prediction mechanistically consistent. Note that this link rests on the general class mechanism, not on drug-specific mechanism data.
Other predictions for this drug are weaker. Alopecia mucinosa, folliculitis decalvans and primary cutaneous B-cell lymphoma have some plausibility but no direct evidence. Predictions for genetic hair disorders and for telogen effluvium have little mechanistic support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11030789 | 2000 | RCT | Archives of Dermatology | Randomized, double-blind, placebo-controlled trial of 0.25% desoximetasone cream in alopecia areata (no abstract available, so results are not summarized here) |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02221918 | TOPICORT | Not specified | Not specified |
| 02221926 | TOPICORT | Not specified | Not specified |
| 02221934 | TOPICORT | Not specified | Not specified |
| 02221896 | TOPICORT | Not specified | Not specified |
Safety Considerations
- Knowledge-graph contraindication signals (from the TxGNN knowledge graph, not from label text): hypopituitarism and related pituitary hormone deficiencies, hypogonadotropic hypogonadism (including Kallmann syndrome), Sheehan syndrome, thymus gland disease, skin atrophy, and peripheral vascular or arterial disease. These should be checked against the official product monograph.
- Drug Interactions: The interaction query returned only a pharmacological target record (glucocorticoid receptor, NR3C1). No drug-drug interactions were identified.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One randomized, double-blind, placebo-controlled trial of desoximetasone 0.25% cream in alopecia areata exists, and the mechanism fits the known class action of topical corticosteroids. However, the trial’s results could not be reviewed, no clinical trials are registered, and the safety data are incomplete. The other nine predicted indications have prediction-only or indirect evidence and should stay on Hold.
To proceed, the following is needed:
- Review of the full text of the 2000 RCT (PMID 11030789) to confirm efficacy, effect size and safety
- Health Canada product monograph warnings and contraindications (a blocking gap for safety screening)
- Dosage form and approved indication details for the four TOPICORT DINs
- Confirmation that the available strengths and formulations suit scalp or hair-bearing skin
- Drug-specific mechanism of action data
- A monitoring plan for local adverse effects such as skin atrophy, and for systemic absorption with prolonged use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.